Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.
Better Therapeutics Inc. (BTTX) is at the forefront of developing prescription digital therapeutics aimed at treating chronic diseases. The company, formerly known as Farewell, leverages a unique combination of software, human coaching enhanced by artificial intelligence, and advanced analytics to address the underlying behaviors causing most chronic conditions. This innovative approach offers scalable solutions capable of impacting millions of lives.
Better Therapeutics' digital therapeutics are grounded in solid evidence and align with existing clinical treatment guidelines. They can be integrated with other interventions or used independently, providing flexible and effective treatment options. The company's non-drug solutions are pivotal in reducing the health and financial burdens of chronic diseases on individuals, healthcare payers, and the broader healthcare system.
Recent achievements include significant advancements in their AI-driven coaching systems and the successful integration of their digital therapeutics into various healthcare settings. Better Therapeutics is continually expanding its partnerships and collaborations to further enhance the reach and effectiveness of its products.
The company's financial health reflects steady growth, driven by its innovative products and expanding market presence. Better Therapeutics remains committed to advancing its mission of improving chronic disease management through cutting-edge digital solutions.
Better Therapeutics (NASDAQ: BTTX) announced the approval of a nonqualified stock option for 200,000 shares to Diane Gomez-Thinnes, its Chief Commercial Officer, as a part of the 2022 Inducement Plan, effective December 1, 2022. The option's exercise price will match the closing stock price on the Grant Date and will vest annually over four years, contingent on her continued service. Better Therapeutics is focused on developing cognitive behavioral therapy solutions for cardiometabolic diseases, aiming to enhance health outcomes while lowering healthcare costs.
Better Therapeutics (NASDAQ: BTTX) announced participation in a virtual fireside chat at the BTIG Digital Health Forum on November 21, 2022, at 2:00 p.m. ET. CEO Frank Karbe and CMO Mark Berman will represent the company, which focuses on innovative digital therapeutics addressing cardiometabolic diseases through cognitive behavioral therapy. Investors can schedule one-on-one meetings during the event. Better Therapeutics aims to transform traditional treatment approaches and improve patient health while reducing healthcare costs with its FDA-regulated software solutions.
Better Therapeutics has reached several key milestones, including the completion of its BT-001 pivotal clinical trial and FDA acceptance of its de novo classification request for marketing authorization of BT-001, a digital therapy targeting type 2 diabetes.
Positive trial results were published in Diabetes Care, showing significant A1c reductions over standard care. The company reported a third-quarter 2022 net loss of $11.4 million, but reduced from $12.5 million year-over-year. Notably, cash reserves declined to $22.3 million from $40.6 million at year-end 2021.
Better Therapeutics, Inc. (NASDAQ: BTTX) will announce its third quarter 2022 financial results on November 14, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET to provide a business update. Better Therapeutics specializes in prescription digital therapeutics using cognitive behavioral therapy to combat cardiometabolic diseases. Their innovative approach aims to alter neural pathways, enabling lasting behavioral changes. If approved, their mobile applications could be prescribed and reimbursed similar to traditional medications.
Better Therapeutics (BTTX) announced the appointment of Diane Gomez-Thinnes as Chief Commercial Officer effective October 26, 2022. With over 20 years in the healthcare sector, her experience includes leading product launches at companies like Johnson & Johnson and Galderma. Gomez-Thinnes will play a crucial role in launching BT-001, a prescription digital therapy for Type 2 Diabetes, currently under FDA review. The therapy aims to provide scalable cognitive behavioral therapy via a smartphone app, targeting underlying causes of cardiometabolic diseases. Positive results from a pivotal clinical trial support its potential effectiveness.
Better Therapeutics, Inc. (NASDAQ: BTTX) announced positive preliminary data from its pivotal trial for BT-001, a digital therapeutic for type 2 diabetes (T2D), recently published in the ADA's peer-reviewed journal, Diabetes Care. The study revealed a 0.4% reduction in A1c levels among users of BT-001 after 90 days compared to a control group. This represents the largest randomized controlled trial using digitally delivered cognitive behavioral therapy (CBT) for T2D to date. The findings support the upcoming FDA submission for BT-001, potentially leading it to become the first prescription digital therapy for T2D.
Better Therapeutics, Inc. (NASDAQ: BTTX) has submitted a de novo request to the FDA for marketing authorization of BT-001, a pioneering digital therapeutic aimed at treating Type 2 Diabetes (T2D) through cognitive behavioral therapy (CBT). This submission follows successful results from a pivotal trial, which showed significant A1c reductions compared to standard medications. If approved, BT-001 would be the first prescription solution of its kind and could potentially address other cardiometabolic conditions. The company aims to offer sustainable, scalable therapy alternatives.
Better Therapeutics (NASDAQ: BTTX), a company focusing on prescription digital therapeutics, has announced its participation in three significant investor conferences in September 2022. These include the H.C. Wainwright 24th Annual Global Investment Conference on September 13, the Lake Street 6th Annual Best Ideas Growth Conference on September 14, and a virtual fireside chat at the LifeSci Partners HealthTech Symposium on September 20. The management team will also hold one-on-one meetings during these events and the fireside chat will be available for replay on their website.
Better Therapeutics, Inc. (NASDAQ: BTTX) recently announced the completion of its pivotal trial for BT-001, a digital therapeutic aimed at treating type 2 diabetes, achieving positive results in both primary and secondary endpoints. The company is set to submit a de novo classification request to the FDA in the third quarter of 2022. Additionally, Better Therapeutics has completed enrollment for the LivVita Liver Study, which evaluates a new treatment for nonalcoholic fatty liver disease. CEO Frank Karbe highlighted the company's growth trajectory, with significant reductions in A1c levels observed in trial participants.
Better Therapeutics, Inc. (NASDAQ: BTTX) will release its second quarter 2022 financial results on August 11, 2022, before market opening. A conference call will be held at 8:30 a.m. ET on the same day to provide a business update. Better Therapeutics specializes in prescription digital therapeutics aimed at addressing cardiometabolic diseases through nutritional cognitive behavioral therapy (nCBT). Their FDA-regulated software-based solutions target conditions like type 2 diabetes and heart disease to improve patient health and reduce healthcare costs.
FAQ
What is the current stock price of BETTER THERAPEUTICS (BTTX)?
What is the market cap of BETTER THERAPEUTICS (BTTX)?
What does Better Therapeutics Inc. do?
How do Better Therapeutics' solutions work?
What makes Better Therapeutics' approach unique?
Can Better Therapeutics' products be used with other treatments?
What recent achievements has Better Therapeutics made?
How does Better Therapeutics impact healthcare costs?
What evidence supports Better Therapeutics' products?
Who can benefit from Better Therapeutics' solutions?
What is the financial condition of Better Therapeutics?
What is the mission of Better Therapeutics?
